Primary hypertension in children and adolescents is an immuno-metabolic disease with hemodynamic consequences

Current Hypertension Reports

Volumn 15, Issue 4, 2013, Pages 331-339

  Litwin, Mieczysław ^a   Michałkiewicz, Jacek ^a,b   Gackowska, Lidia ^b  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Adolescents; Blood pressure; BP; Cardiovascular disease; Children; CVD; Cytokines; Immune activity; Metabolic syndrome; PH; Primary hypertension; T regulatory cells; Target organ damage; TOD; Treatment; Visceral obesity

Indexed keywords

ADIPONECTIN RECEPTOR 1; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CD4 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; N(G),N(G) DIMETHYLARGININE; RANTES; REACTIVE OXYGEN METABOLITE;

ADOLESCENT HEALTH; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE VARIABILITY; CHILD DEVELOPMENT; CHILD HEALTH; DISEASE ASSOCIATION; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; IMMUNOPATHOLOGY; METABOLIC DISORDER; MOLECULAR PATHOLOGY; NONHUMAN; ORGAN INJURY; OXIDATIVE STRESS; PHENOTYPE; PROTEIN EXPRESSION;

ADOLESCENT; ANIMALS; ANTIHYPERTENSIVE AGENTS; CHILD; HEMODYNAMICS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 84880919503     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0360-5     Document Type: Article

References (63)

1. Barker DJP, Osmond C, Golding J, Kuh D, Wadsworth MEJ. Growth in utero, blood pressure in childhood, and adult life, and mortality from cardiovascular disease. BMJ. 1989;298:564-7.
2. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007;298:874-9.
3. Daniels SR, Loggie JM, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation. 1998;97:1907-11.
4. Kułaga Z, Litwin M, Grajda A, et al. Oscilllometric blood pressure percentiles for Polish normal-weight children. J Hypertens. 2012;30:1942-54.
5. Flynn JT, Alderman MH. Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol. 2005;20:961-6.
6. Robinson RF, Batisky DL, Hayes JR, Nahata MC, Mahan JD. Body mass index in primary and secondary pediatric hypertension. Pediatr Nephrol. 2004;19:1379-84.
7. Pludowski P, Litwin M, Sladowska J, et al. Bone mass and body composition in children and adolescents with primary hypertension. Hypertension. 2008;51:77-83.
8. Litwin M, Śladowska J, Syczewska M, et al. Different BMI cardiovascular risk thresholds as markers of organ damage and metabolic syndrome in primary hypertension. Pediatr Nephrol. 2008;23:787-96.
9. Litwin M, Trelewicz J, Wawer ZT, et al. Intima-media thickness and functional properties of arterial wall in elastic and muscular type arteries in children and adolescents with arterial hypertension: controlled study. Pediatr Nephrol. 2004;19:767-74.
10. •• Markus MRP, Stritzke J, Siewert U, et al. Variation in body composition determines long-term blood pressure changes in prehypertension. J Am Coll Cardiol. 2010;56:65-76. Prospective study showing that maintenance of healthy body weight and fitness is associated with maintenance of normal blood pressure over time in older adults.
11. Tirosh A, Afek A, Rudich A, et al. Progression of normotensive adolescent into hypertensive adults. Hypertension. 2010;56:203-9.
12. •• Lever AF, Harrap SB. Essential hypertension: a disorder of growth with origins in childhood ? J Hypertens. 1992;10:101-20. Presentation of hypothesis linking tempo of development and growth spurt with metabolic abnormalities and elevation of blood pressure.
13. Hamilton M, Pickering GW, Roberts JAF, Sowry GSC. The aetiology of essential hypertension I. The arterial pressure in the general population. Clin Sci. 1954;13:273-304.
14. • Katz SH, Hediger ML, Shall JI, et al. Blood pressure, growth, maturation from childhood through adolescence: mixed longitudinal analyses from Philadelphia Blood Pressure Project. Hypertension. 1980;2 Suppl 1:55-69. This study describes relationship between acceleration of biological maturation with elevated blood pressure in adolescents.
15. • Pludowski P, Litwin M, Niemirska A, et al. Accelerated skeletal maturation in children with primary hypertension. Hypertension. 2009;54:1234-9. This study describes differences in biological maturation expressed as difference between bone age and chronological age in relation to blood pressure status.
16. Kułaga Z, Litwin M, Tkaczyk M, et al. Polish 2010 growth references for school aged children and adolescents. Eur J Pediatr. 2011;170:599-609.
17. • Halldorsson T, Gunnarsdottir I, Birgisdottir BE, et al. Childhood growth and adult hypertension in a population of high birth weight. Hypertension. 2010;58:8-15. Retrospective study confirming relationship between acceleration of biological development and later development of arterial hypertension in males.
18. • Kivimaki M, Lawlor DA, Smith DG, et al. Association of the age of menarche with cardiovascular risk factors, vascular structure and function in adulthood: the cardiovascular risk in young Finns study. Am J Clin Nutr. 2008;87:1876-82. This study describes relationship between acceleration of biological development with risk of metabolic syndrome and arterial hypertension in young adulthood in women.
19. Litwin M, Śladowska J, Antoniewicz J, et al. Metabolic abnormalities, insulin resistance and metabolic syndrome in children with primary hypertension. Am J Hypertens. 2007;20:875-82.
20. • Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247-52. This study describes elevation of serum uric acid concentrations as most typical metabolic abnormality in children with primary hypertension.
21. Feig DI, Soletsky B, Johnosn RJ. Effect of allopurinol on blood pressure of adolescent with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300:924-32.
22. • Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60:1148-56. These two studies are the first pediatric studies reporting effects of allopurinol and probenecid on decrease of blood pressure in hypertensive [21] and pregypertensive [22] adolescents.
23. Turi S, Friedman A, Bereczki C, et al. Oxidative stress in juvenile hypertension. J Hypertens. 2003;21:145-52.
24. • Sladowska-Kozlowska J, Litwin M, Niemirska A, et al. Oxidative stress in hypertensive children before and after 1 year of antihypertensive treatment. Pediatr Nephrol. 2012;27:1943-51. It is the first prospective study reporting results of antihypertensive treatment on oxidative stress in children with primary hypertension and relation between OSX and target organ damage.
25. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy man. Hypertension. 2001;38:399-403.
26. Festa A, Agostino Jr, Howard G, et al. Chronic subclinical inflammation as a part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-7.
27. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly. The Cardiovascular Health Study. Diabetes. 2001;50:2384-9.
28. Fernandez-Real JM, Ricard W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301.
29. Litwin M, Michalkiewicz J, Niemirska A, et al. Inflammatory activation in children with primary hypertension. Pediatr Nephrol. 2010;25:2489-99.
30. Harrison DG, Vinch A, Lob, Mahdur MS. Role of adaptive immune system in hypertension. Curr Opin Pharmacol. 2010;10:203-7.
31. •• Harrison DG, Guzik TJ, Lob H, et al. Inflammation, immunity and hypertension. Hypertension. 2011;57:132-40. This review describes most important immunological phenomena found in experimental studies and presents hypothesis explaining the role of immune system in pathogenesis of arterial hypertension.
32. Jurewicz M, McDermott DH, Sechler JM, et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin induced inflammation. J Am Soc Nephrol. 2007;18:1093-102.
33. Hoch NE, Guzik TJ, Chen W, et al. Regulation of T cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2009;296:R208-16.
34. Benicky J, Sanchez-Lemus E, Pavel J, Saavedra JM. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Moll Neurobiol. 2009;29:781-92.
35. Chon H, Gaillard CAJM, van der Meijden BB, et al. Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension. 2004;43:947-51.
36. Coppo M, Bandinelli M, Berni A et al. Ang-II upregulation of T lymphocyte renin-angiotensin system is amplified by low-grade inflammation in human hypertension. Am J Hypertens. 2011;24: 716-723.
37. Timofeeva AW, Goryunova LE, Khaspekov GL et al. Altered gene expression pattern in peripheral blood leucocytes from patients with arterial hypertension. Ann NY Acad Sci. 2006;1091:319-335.
38. Litwin M, Michałkiewicz, Trojanek J, et al. Altered genes profile of renin-angiotensin system, immune system, and adipokines receptors in leukocytes of children with primary hypertension. Hypertension. 2013;61:431-6.
39. Marvar PJ, Thabet SR, Guzik TJ, et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II -induced hypertension. Circ Res. 2010;107:263-70.
40. •• Guzik TJ, Hoch NE, Brown KA, et al. Role of T cells in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-60. In this experimental study role of T cells in pathogenesis of angiotensin-dependent hypertension has been studied.
41. Marvar PJ, Vinch A, Thabet S, et al. T lymphocytes and vascular inflammation contribute to stress-dependent hypertension. Biol Psychiatry. 2012;71:774-82.
42. •• Barhoumi T, Kasal DA, Li MW, et al. T regulatory lymphocytes prevent angiotensin II induced hypertension and vascular injury. Hypertension. 2011;57:469-76. A description of the role of T-regs in pathogenesis of arterial injury and elevation of blood pressure.
43. Zhang W, Wang W, Yu H, et al. Interleukin 6 underlies angiotensin II induced hypertension and chronic renal damage. Hypertension. 2012;59:136-44.
44. Coppo M, Boddi M, Bandinelli M, et al. Angiotensin II up-regulates renin-angiotensin system in human isolated T lymphocytes. Regul Pept. 2008;151:1-6.
45. • Marchesi C, Dentali F, Nicolini E, et al. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and metaanalysis. J Hypertens. 2012;30:3-16. A detailed metaanalysis of studies describing role of MMPs and TIMPs in arterial hypertension.
46. Cheng M, Hashmi S, Mao X, Zeng QT. Relationship of adiponectin matrix metallloproteinase-9 to tissue inhibitor of metallloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. Can J Cardiol. 2008;24:385-90.
47. Głowińska-Olszewska B, Urban M. Elevated matrix metallloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adoelscents. Metabolism. 2007;56:799-805.
48. Niemirska A, Trojanek J, Michałkiewicz J, Litwin M. Altered matrix metalloproteinases 9 and tissue inhibitor of metalloproteinases 1 activities in children with primary hypertension. 23rd European Meeting on Hypertension and Cardiovascular Protection 2013 (abstract).
49. Stabouli S, Kotsis V, Rizos Z, et al. Left ventricular mass in normotensive, prehypertensive and hypertensive children and adolescents. Pediatr Nephrol. 2009;24:1545-51.
50. Sorof JM, Cardwell G, Franco K, Portman RJ. Ambulatory blood pressure and left ventricular mass in hypertensive children. Hypertension. 2002;39:903-8.
51. Litwin M, Niemirska A, Ruzicka M, Feber J. White coat hypertension in children: not rare and not benign? J Am Soc Hypertens. 2009;3:416-23.
52. Litwin M, Niemirska A, Sladowska J, et al. Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. Pediatr Nephrol. 2006;21:811-9.
53. • Litwin M, Niemirska, Sladowska-Kozłowska J, et al. Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol. 2010;25:2489-99. One of the few pediatric prospective studies evaluating effects of antihypertesive treatment on target organ damage and metabolic abnormalities in children with primary hypertension.
54. Sladowska-Kozlowska J, Litwin M, Niemirska A, et al. Change in left ventricular geometry during antihypertensive treatment in children with primary hypertension. Pediatr Nephrol. 2011;26:2201-9.
55. Richey PA, Disessa TG, Hastings MC, et al. Ambulatory blood pressure and increased left ventricular mass in children at risk for hypertension. J Pediatr. 2008;152:343-8.
56. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on Diagnosis, Evaluation and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics. 2004;114:555-76.
57. • Lurbe E, Cifkova R, Cruickshank JK, et al. European Society of Hypertension. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719-42. The first European Society of Hypertension guidelines concerning treatment of arterial hypertension in children and discussing the significance of metabolic abnormalities in primary hypertension.
58. Schaefer F, Litwin M, Zachwieja J, et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens. 2011;29:2484-90.
59. Schaefer F, van de Walle J, Zurowska A, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28:1083-90.
60. Niemirska A, Litwin M, Feber J. Changes in mean arterial pressure/heart rate rhythmicity, target organ damage and visceral obesity in hypertrensive boys on antihypertensive therapy. Pediatr Nephrol. 2012;27:1761. abstract.
61. • O'Rourke MF, Adji A. Guidelines on guidelines: focus on isolated hypertension in youth. J Hypertens. 2013;31:649-54. Important discussion of hemodynamic phenomena of increased brachial blood pressure despite normal central blood pressure in young men.
62. •• Johnson RJ, Rodriguez-Iturbe B, Nakagawa T, Kang DH, Feig DI, Herrera-Acosta J. Subtle renal injury is likely a common mechanism for salt-sensitive essential hypertension. Hypertension. 2005;45:326-30. Presentation of hypothesis linking primary activation of sympathetic nervous system with arteriolar constriction, metabolic abnormalities and evolution to sodium dependent hypertension.
63. • Zubcevic J, Waki H, Raizada MK, Paton JFR. Autonomic-immune- vascular interaction: an emerging concept for neurogenic hypertension. Hypertension. 2011;57:1026-33. Review of experimental studies showing interactions between immune vascular injury and activation of autonomic centers in central nervous system.